Ultomiris Dosing Calculator The calculator below may help you to calculate the necessary values to infuse your patients with ULTOMIRIS® (ravulizumab) 100 mg/mL.
ULTOMIRIS® is available as 300 mg/3 mL and 1,100 mg/11 mL concentrates for solution for infusion. This calculator is intended for use when administering doses of ULTOMIRIS® 100 mg/mL only.** For dosing information regarding ULTOMIRIS® 10 mg/mL (300 mg/30 mL), please see the full Summary of Product Characteristics.1

In the absence of compatibility studies, ULTOMIRIS® 300 mg/30 mL concentrate for solution for infusion must not be mixed with ULTOMIRIS® 300 mg/3 mL or 1,100 mg/11 mL concentrates for solution for infusion.1

Drag the button across the slider bar in order to select your patient's body weight (kg). The body weight variable will automatically snap to the nearest recognised figure in line with the ULTOMIRIS® weight-based dosing.
Note: For patients switching from SOLIRIS® (eculizumab) to ULTOMIRIS®, the loading dose of ULTOMIRIS® should be administered 2 weeks after the last SOLIRIS® infusion§, and then maintenance doses should be administered per weight-based dosing regimen.1
ULTOMIRIS® SmPC

*This dosing calculator is intended for use by healthcare professionals only. All calculations must be confirmed before administration. The information provided does not replace clinical judgment. Please also refer to the Summary of Product Characteristics before prescribing and administration.

†ULTOMIRIS® must be administered by a healthcare professional and under the supervision of a physician experienced in the management of patients with haematological or renal, neuromuscular or neuroinflammatory disorders.1

‡ULTOMIRIS® should only be diluted using sodium chloride 9mg/mL (0.9%) solution for injection.1

§SOLIRIS® (eculizumab) is indicated for the treatment of PNH.3

Patients must be vaccinated against meningococcal infection at least 2 weeks prior to initiating treatment, or if vaccinated <2 weeks of initiation of treatment must receive prophylactic treatment with appropriate antibiotics until 2 week after vaccination.1

#First maintenance dose is administered 2 weeks after loading dose.1
Please report any adverse events via your national reporting system. Adverse events can also be reported to Alexion, AstraZeneca Rare Disease by contacting: https://contactazmedical.astrazeneca.com/
advance I am a healthcare professional registered in the EU I am not a
healthcare professional
PNH, paroxysmal nocturnal haemoglobinuria; SmPC, summary of product characteristics.                                                                                                                                       
ULTOMIRIS® EU Summary of Product Characteristics available at: https://www.ema.europa.eu/en/documents/product-information/ultomiris-epar-product-information_en.pdf. Last accessed January 2026. SOLIRIS® EU Summary of Product Characteristics available at: https://www.ema.europa.eu/en/documents/product-information/ultomiris-epar-product-information_en.pdf. Last accessed January 2026. SOLIRIS® EU Summary of Product Characteristics available at: https://www.ema.europa.eu/en/documents/product-information/ultomiris-epar-product-information_en.pdf. Last accessed January 2026.